Skip to content
RDL Network logo
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial — Elisa A. Rozeman (2019) | RDL Network